Literature DB >> 15085947

A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs.

Douwe de Boer1, Ingrid Bosman.   

Abstract

OBJECTIVE: To collect data related to phenethylamine drugs-of-abuse of the 2C-series, to review possible health risks of their use and to discuss legal counter actions of authorities in the European Union (EU). SETTINGS: Dutch smartshops.
METHODS: In the period of 1994-2002, all products that were claimed to contain synthetic drugs and sold in the smartshops, were purchased. The contents were analysed using analytical chemical technologies such as gas chromatography/mass spectrometry and nuclear magnetic resonance. Additionally, using computerised searches in relevant databases and checking cross-references, literature and documents were screened for scientific based information.
RESULTS: All purchased products proved to be tablets, of which most of them contained one of the phenethylamine designer drugs 2C-B, 2C-T-2 or 2C-T-7. The different drugs were introduced on the Dutch smartshop market within time intervals of approximately three years. The information that was supplied on leaflets and accompanied the products sometimes appeared to be extensive, but was partly misleading and incorrect. Besides that, scientific based information in respect to health risks of drugs of the 2C-series and the detection of their abuse was scarce. Until now no intoxications have been reported in the EU and no centralised legal actions have been taken to prevent possible intoxications.
CONCLUSIONS: The lack of observed intoxications may justify the absence of legal actions in the EU against phenethylamine designer drugs-of-abuse of the 2C-series. However, this may also be explained by either the inability of toxicologists to detect the abuse of substances of the 2C-series or the unawareness of the phenomenon of these drugs. Therefore, EU authorities should promote the availability of relevant standards, validated assays and scientific knowledge regarding these drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085947     DOI: 10.1023/b:phar.0000018600.03664.36

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  6 in total

1.  Computational study of IR, Raman, and NMR spectra of 4-methylmethcathinone drug.

Authors:  Valentina Minaeva; Boris Minaev; Alexander Panchenko; Vyacheslav Pasychnik
Journal:  J Mol Model       Date:  2021-01-02       Impact factor: 1.810

2.  Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats.

Authors:  William E Fantegrossi; Andrew W Harrington; Justin R Eckler; Sadia Arshad; Richard A Rabin; Jerrold C Winter; Andrew Coop; Kenner C Rice; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

3.  Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.

Authors:  Tomáš Páleníček; Michaela Fujáková; Martin Brunovský; Jiří Horáček; Ingmar Gorman; Marie Balíková; Lukáš Rambousek; Kamila Syslová; Petr Kačer; Petr Zach; Věra Bubeníková-Valešová; Filip Tylš; Anna Kubešová; Jana Puskarčíková; Cyril Höschl
Journal:  Psychopharmacology (Berl)       Date:  2012-07-29       Impact factor: 4.530

4.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Authors:  Amy J Eshleman; Michael J Forster; Katherine M Wolfrum; Robert A Johnson; Aaron Janowsky; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-19       Impact factor: 4.530

5.  The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Authors:  P Mallaroni; N L Mason; F R J Vinckenbosch; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2022-04-30       Impact factor: 4.415

6.  Acute Pharmacological Effects of 2C-B in Humans: An Observational Study.

Authors:  Esther Papaseit; Magí Farré; Clara Pérez-Mañá; Marta Torrens; Mireia Ventura; Mitona Pujadas; Rafael de la Torre; Débora González
Journal:  Front Pharmacol       Date:  2018-03-13       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.